ArticleCancers2026

Naloxegol, an Oral Peripherally Acting Opioid Receptor Antagonist, Administered Concurrently with First-Line Systemic Therapy for Advanced Lung Adenocarcinoma (Alliance A221504): A Feasibility and Safety Study.

Pankaj Gupta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.